From my own thoughts and experience, when we can get a viral load testing apparatus that is low cost and can be used at the point of care, then we can increase efficiency of managing patients on ART, reduce the prospect for resistance and reduce the chances of loosing people to second line regimen. I have had friend struggle with failed regimen and having to look for friends in developing countries to source for their salvage therapy
I agree that among the important things is the therapeutic adherence intervention. another strategy in virologically suppressed stable patients with protease inhibitor is the de-intesification
The point-of-care needs of a developing country have to do with HIV testing and monitoring of therapeutic effectiveness. Sensitive, specific, low-cost, easy-to-use, low-maintenance devices for measuring CD4 count, HIV viral load, and for diagnosing HIV are needed (the latter is important in children under 18 months, for whom definitive diagnosis is problematic in resource-limited settings) .